Sarper Toker

1.5k total citations · 1 hit paper
13 papers, 634 citations indexed

About

Sarper Toker is a scholar working on Oncology, Obstetrics and Gynecology and Epidemiology. According to data from OpenAlex, Sarper Toker has authored 13 papers receiving a total of 634 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Obstetrics and Gynecology and 5 papers in Epidemiology. Recurrent topics in Sarper Toker's work include Endometrial and Cervical Cancer Treatments (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Cervical Cancer and HPV Research (4 papers). Sarper Toker is often cited by papers focused on Endometrial and Cervical Cancer Treatments (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Cervical Cancer and HPV Research (4 papers). Sarper Toker collaborates with scholars based in United States, Italy and Japan. Sarper Toker's co-authors include Ronnie Shapira‐Frommer, Domenica Lorusso, Stephen J. O’Keefe, Kan Li, Pamela Salman, Vanessa Samouëlian, Mivael Olivera, Vincent Castonguay, Coraline Dubot and Krishnansu S. Tewari and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Sarper Toker

11 papers receiving 623 citations

Hit Papers

Pembrolizumab for Persistent, Recurrent, or Metastatic Ce... 2021 2026 2022 2024 2021 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
    2021 581 citations Nicoletta Colombo, Coraline Dubot et al. New England Journal of Medicine profile →

Peers

Sarper Toker
Arkhipov Alexander Russia
M. Valeria Cáceres Argentina
Mivael Olivera Peru
Steven DeCesare United States
Juan Carlos Alcedo United Kingdom
Mignon-Denise Keyver-Paik Germany
Robert Orlowski United States
Damiano Arciuolo Italy
Shinichi Togami Japan
Lynne Eaton United States
Arkhipov Alexander Russia
Sarper Toker
Citations per year, relative to Sarper Toker Sarper Toker (= 1×) peers Arkhipov Alexander

Countries citing papers authored by Sarper Toker

Since Specialization
Citations

This map shows the geographic impact of Sarper Toker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarper Toker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarper Toker more than expected).

Fields of papers citing papers by Sarper Toker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarper Toker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarper Toker. The network helps show where Sarper Toker may publish in the future.

Co-authorship network of co-authors of Sarper Toker

This figure shows the co-authorship network connecting the top 25 collaborators of Sarper Toker. A scholar is included among the top collaborators of Sarper Toker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarper Toker. Sarper Toker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Monk, Bradley J., Manish R. Patel, Sarper Toker, Vivek Subbiah, & Lucio Gordan. (2025). Development of anti-cancer medicines in the current era. Cancer Treatment and Research Communications. 45. 101002–101002.
2.
3.
4.
Monberg, Matthew, Vassiliki Karantza, Konstantinos Tryfonidis, et al.. (2024). A Narrative Review of the Clinical, Humanistic, and Economic Value of Pembrolizumab-Based Immunotherapy for the Treatment of Breast and Gynecologic Cancers. Oncology and Therapy. 12(4). 701–734. 1 indexed citations
5.
Duska, Linda, Yang Xiang, Kosei Hasegawa, et al.. (2024). Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study. Gynecologic Oncology. 190. S8–S9. 3 indexed citations
6.
7.
8.
Tewari, Krishnansu S., Nicoletta Colombo, Bradley J. Monk, et al.. (2023). Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. JAMA Oncology. 10(2). 185–185. 21 indexed citations
9.
Colombo, Nicoletta, Coraline Dubot, Domenica Lorusso, et al.. (2022). Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. Obstetrical & Gynecological Survey. 77(1). 30–31. 10 indexed citations
10.
Tewari, Krishnansu S., Nicoletta Colombo, Bradley J. Monk, et al.. (2022). Pembrolizumab + chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: Subgroup analysis of KEYNOTE-826.. Journal of Clinical Oncology. 40(16_suppl). 5506–5506. 9 indexed citations
11.
Colombo, Nicoletta, Coraline Dubot, Domenica Lorusso, et al.. (2021). Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. New England Journal of Medicine. 385(20). 1856–1867. 581 indexed citations breakdown →
12.
Rasco, Drew, Nehal J. Lakhani, Ryan P. Sullivan, et al.. (2018). Abstract CT019: ASN003, a novel highly selective BRAF and PI3K dual inhibitor: Phase I PK/PD results in patients with advanced solid tumors. Cancer Research. 78(13_Supplement). CT019–CT019. 1 indexed citations
13.
Barta, Stefan K., Drew Rasco, Andy I. Chen, et al.. (2018). Clinical activity, safety and tolerability of ASN002, a dual JAK/SYK inhibitor, in patients with non-Hodgkin lymphoma (NHL), myeolfibrosis (MF), chronic lymphocytic leukemia (CLL) and solid tumors.. Journal of Clinical Oncology. 36(15_suppl). TPS7084–TPS7084. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Arkhipov Alexander Breakdown of academic impact, for papers by M. Valeria Cáceres Breakdown of academic impact, for papers by Mivael Olivera Breakdown of academic impact, for papers by Steven DeCesare Breakdown of academic impact, for papers by Juan Carlos Alcedo Breakdown of academic impact, for papers by Mignon-Denise Keyver-Paik Breakdown of academic impact, for papers by Robert Orlowski Breakdown of academic impact, for papers by Damiano Arciuolo Breakdown of academic impact, for papers by Shinichi Togami Breakdown of academic impact, for papers by Lynne Eaton
Rankless by CCL
2026